TjaÅ¡a Cerar

List of Publications by Year in descending order

48 papers	1,529 citations	471509 17 h-index	302126 39 g-index
51 all docs	51 docs citations	51 times ranked	1929 citing authors

#	ARTICLE	IF	CITATIONS
1	Ecology and prevalence of Borrelia burgdorferi s.l. in Ixodes ricinus (Acari: Ixodidae) ticks. Acta Veterinaria Hungarica, 2022, , .	0.5	0
2	Evaluation of two rapid phenotypical testsâ€"Alifax rapid AST colistin test and Rapid Polymyxin NP testâ€"for detection of colistin resistance in Enterobacterales. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1749-1753.	2.9	3
3	Genetic diversity and the presence of circular plasmids in Bacillus cereus isolates of clinical and environmental origin. Archives of Microbiology, 2021, 203, 3209-3217.	2.2	1
4	Characterization of Tularemia Cases in Slovenia with Multiple-Locus Variable-Number Tandem Repeat Analysis. Vector-Borne and Zoonotic Diseases, 2021, 21, 351-357.	1.5	1
5	Legionella pneumophilaâ€"Epidemiology and Characterization of Clinical Isolates, Slovenia, 2006â€"2020. Diagnostics, 2021, 11, 1201.	2.6	7
6	Clinical manifestations and longâ€term outcome of early Lyme neuroborreliosis according to the European Federation of Neurological Societies diagnostic criteria (definite versus possible) in central Europe. A retrospective cohort study. European Journal of Neurology, 2021, 28, 3155-3166.	3.3	9
7	Systemic immune responses in patients with early localized or early disseminated Borrelia afzelii lyme borreliosis. Immunity, Inflammation and Disease, 2021, 9, 375-387.	2.7	1
8	Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans. PLoS ONE, 2021, 16, e0261194.	2.5	2
9	Effect of Statin Use on the Clinical Manifestations, Laboratory Test Results and Outcome of Lyme Neuroborreliosis. Journal of Clinical Medicine, 2020, 9, 2995.	2.4	2
10	Evaluation of real-time PCR targeting the lipL32 gene for diagnosis of Leptospira infection. BMC Microbiology, 2020, 20, 59.	3.3	26
11	Whole genome sequencing characterization of Slovenian carbapenem-resistant Klebsiella pneumoniae, including OXA-48 and NDM-1 producing outbreak isolates. PLoS ONE, 2020, 15, e0231503.	2.5	8
12	Cross-border spread of blaNDM-1- and blaOXA-48-positive Klebsiella pneumoniae: a European collaborative analysis of whole genome sequencing and epidemiological data, 2014 to 2019. Eurosurveillance, 2020, 25, .	7.0	26
13	Title is missing!. , 2020, 15, e0231503.		0
14	Title is missing!. , 2020, 15, e0231503.		0
15	Title is missing!. , 2020, 15, e0231503.		0
16	Title is missing!. , 2020, 15, e0231503.		0
17	Evaluation of resazurin-based rapid test to detect colistin resistance in Acinetobacter baumannii isolates. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 2159-2162.	2.9	14
18	Antibiotic Use and Long-Term Outcome in Patients with Tick-Borne Encephalitis and Co-Infection with Borrelia Burgdorferi Sensu Lato in Central Europe. A Retrospective Cohort Study. Journal of Clinical Medicine, 2019, 8, 1740.	2.4	5

#	Article	IF	Citations
19	Evaluation of a novel epidemiological screening approach for detection of colistin resistant human Enterobacteriaceae isolates using a selective SuperPolymyxin medium. Journal of Microbiological Methods, 2019, 160, 117-123.	1.6	7
20	Borrelia burgdorferi sensu lato infection in patients with peripheral facial palsy. Ticks and Tick-borne Diseases, 2019, 10, 398-406.	2.7	13
21	Surveillance cultures for detection of rectal and lower respiratory tract carriage of colistin-resistant Gram-negative bacilli in intensive care unit patients: comparison of direct plating and pre-enrichment step. Journal of Medical Microbiology, 2019, 68, 1269-1278.	1.8	4
22	Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1352-1358.	3.0	21
23	Clinical Course, Serologic Response, and Long-Term Outcome in Elderly Patients with Early Lyme Borreliosis. Journal of Clinical Medicine, 2018, 7, 506.	2.4	21
24	Comparison of Clinical Course and Treatment Outcome for Patients With Early Disseminated or Early Localized Lyme Borreliosis. JAMA Dermatology, 2018, 154, 1050.	4.1	27
25	Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infectious Diseases, The, 2017, 17, 153-163.	9.1	522
26	Progress in the molecular diagnosis of Lyme disease. Expert Review of Molecular Diagnostics, 2017, 17, 19-30.	3.1	34
27	Comparison of MKP and BSK-H media for the cultivation and isolation of Borrelia burgdorferi sensu lato. PLoS ONE, 2017, 12, e0171622.	2.5	12
28	Differences in Genotype, Clinical Features, and Inflammatory Potentialof Borrelia burgdorferisensu stricto Strains from Europe and the United States. Emerging Infectious Diseases, 2016, 22, 818-827.	4.3	76
29	Comparison of Growth of Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi Sensu Stricto at Five Different Temperatures. PLoS ONE, 2016, 11, e0157706.	2.5	8
30	Course and Outcome of Early European Lyme Neuroborreliosis (Bannwarth Syndrome): Clinical and Laboratory Findings. Clinical Infectious Diseases, 2016, 63, 346-353.	5.8	103
31	Borrelia Genotyping in Lyme Disease. Open Dermatology Journal, 2016, 10, 6-14.	0.3	7
32	Broad-Range 16S rDNA PCR on Heart Valves in Infective Endocarditis. Journal of Heart Valve Disease, 2016, 25, 221-226.	0.5	1
33	First recovery of Rasamsonia argillacea species complex isolated in adolescent patient with cystic fibrosis in Slovenia â€“ case report and review of literature. Mycoses, 2015, 58, 506-510.	4.0	13
34	Detection, identification and genotyping of Borrellia spp. in rodents in Slovenia by PCR and culture. BMC Veterinary Research, 2015, 11, 188.	1.9	16
35	Evaluation of the immunochromatographic (Leptocheck) test for detection of specific antibodies against leptospires. Wiener Klinische Wochenschrift, 2015, 127, 948-953.	1.9	7
36	Influence of MKP medium stored for prolonged periods on growth and morphology ofBorrelia afzelii, Borrelia garinii, and Borrelia burgdorferisensu stricto. Apmis, 2014, 122, 230-235.	2.0	5

#	Article	IF	Citations
37	Suspected Early Lyme Neuroborreliosis in Patients With Erythema Migrans. Clinical Infectious Diseases, 2013, 57, 501-509.	5.8	44
38	In vitro susceptibility of European human Borrelia burgdorferi sensu stricto strains to antimicrobial agents. International Journal of Antimicrobial Agents, 2013, 41, 288-291.	2.5	16
39	Treatment of Erythema Migrans With Doxycycline for 10 Days Versus 15 Days. Clinical Infectious Diseases, 2012, 55, 343-350.	5.8	76
40	Comparison of Post-Lyme Borreliosis Symptoms in Erythema Migrans Patients with Positive and Negative Borrelia burgdorferi Sensu Lato Skin Culture. Vector-Borne and Zoonotic Diseases, 2011, 11, 883-889.	1.5	24
41	Lactococcus garvieae septicaemia in a patient with artificial heart valves. Wiener Klinische Wochenschrift, 2011, 123, 677-679.	1.9	9
42	Humoral Immune Responses in Patients with Lyme Neuroborreliosis. Vaccine Journal, 2010, 17, 645-650.	3.1	32
43	Evaluation of real-time PCR targeting hbb gene for Borrelia species identification. Journal of Microbiological Methods, 2010, 82, 115-119.	1.6	19
44	Subjective Symptoms after Treatment of Early Lyme Disease. American Journal of Medicine, 2010, 123, 79-86.	1.5	166
45	Protein profile determination of Borrelia afzelii and Borrelia garinii isolated from skin and cerebrospinal fluid. World Journal of Microbiology and Biotechnology, 2009, 25, 1287-1296.	3.6	1
46	Comparison of PCR methods and culture for the detection of Borrelia spp. in patients with erythema migrans. Clinical Microbiology and Infection, 2008, 14, 653-658.	6.0	39
47	Validation of Cultivation and PCR Methods for Diagnosis of Lyme Neuroborreliosis. Journal of Clinical Microbiology, 2008, 46, 3375-3379.	3.9	89
48	Comparison of immunofluorescence assay (IFA) and LIAISONÂ® in patients with different clinical manifestations of Lyme borreliosis. Wiener Klinische Wochenschrift, 2006, 118, 686-690.	1.9	12